Clik here to view.
One-Year Results in Japanese Clinical Study Affirms the GORE® VIABAHN®...
FLAGSTAFF, Ariz. & LAS VEGAS W. L. Gore & Associates, Inc. (Gore) today announced positive results from a prospective, multicenter Investigational Device Exemption (IDE) Clinical Study of...
View ArticleClik here to view.
Acelity Announces Early Tender Results for the Exchange Offer and Successful...
SAN ANTONIO Acelity L.P. Inc. (“Acelity”), a global advanced wound care and regenerative medicine company, today announced the results, as of 5:00 p.m., New York City time, on September 19, 2016...
View ArticleClik here to view.
Takeda and Affilogic enter into Research Collaboration to Develop...
OSAKA, Japan & NANTES, France Takeda Pharmaceutical Company Limited (TSE: 4502) and Affilogic today jointly announced that the companies have entered into a research collaboration to explore...
View ArticleClik here to view.
サンバイオ、日本における外傷性脳損傷を対象としたフェーズ２臨床試験開始のお知らせ
東京 （ビジネスワイヤ） — サンバイオ株式会社（本社:東京都中央区、代表取締役社長：森 敬太）は、本日、神経系疾患を対象に日米で開発を進めている再生細胞薬SB623（以下、「本剤」）の外傷性脳損傷を対象としたフェーズ２臨床試験を国内で開始しましたので、お知らせします。...
View ArticleClik here to view.
GORE® TAG® Thoracic Branch Endoprosthesisのピボタル試験で初の植え込みが完了
米アリゾナ州フラッグスタッフ （ビジネスワイヤ） — W. L. Gore & Associates, Inc.（ゴア）は本日、ピボタル試験でGORE® TAG® Thoracic Branch...
View ArticleClik here to view.
SanBio Begins Clinical Trial of Regenerative Cell Medicine for Patients with...
MOUNTAIN VIEW, Calif. SanBio Co., Ltd., a scientific leader in regenerative medicine for neurological disorders, announced today that it has begun a Phase 2 clinical trial of regenerative cell...
View ArticleClik here to view.
SAB Biotherapeutics的免疫治疗药物提案跻身WHO报告中的顶级平台技术解决方案之列
马里兰州贝塞斯达和南达科他州苏福尔斯 (美国商业资讯) — 临床阶段生物制药开发企业SAB Biotherapeutics (SAB)今天宣布，其DiversitAb人类抗体生产平台被确认为世界卫生组织(WHO)针对有大流行可能的优先感染性疾病的平台技术公开磋商中涌现的6个最有价值提案之一，该平台发挥了转染色体牛(Tc Bovine™)的优势。...
View ArticleClik here to view.
Gyros Protein Technologies Establishes Dedicated Office in Japan
UPPSALA, Sweden Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has established a...
View ArticleClik here to view.
GE Healthcare Aims to Fund up to $50M for Global Health Startups
BANGALORE, India GE Healthcare, the $18 billion healthcare technology division of GE (NYSE: GE), today announced the launch of the company’s first healthcare accelerator, five.eight, aimed at...
View ArticleClik here to view.
Alexion Employees Volunteer Together in Company’s First Global Day of Service
NEW HAVEN, Conn. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company’s...
View ArticleClik here to view.
One-Year Results in Japanese Clinical Study Affirms the GORE® VIABAHN®...
FLAGSTAFF, Ariz. & LAS VEGAS W. L. Gore & Associates, Inc. (Gore) today announced positive results from a prospective, multicenter Investigational Device Exemption (IDE) Clinical Study of...
View ArticleClik here to view.
Pharmaron and MSD Agree Deal to Acquire MSD’s UK Hoddesdon Site
BEIJING Pharmaron has entered into a non-binding Heads of Terms (HoTs) with Merck Sharpe & Dohme Limited (MSD) for the sale of the Hoddesdon UK site which includes MSD’s process development and...
View ArticleClik here to view.
SAB Biotherapeuticsの免疫療法に関する提案がWHO報告書で優秀なプラットフォーム技術ソリューションの1つに選ばれる
米メリーランド州ベセスダ & 米サウスダコタ州スーフォールズ （ビジネスワイヤ） — 臨床段階のバイオ医薬品開発企業SAB Biotherapeutics（SAB）は本日、染色体導入ウシ（Tc...
View ArticleClik here to view.
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3...
SOUTH SAN FRANCISCO, Calif. Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 pivotal trial to...
View ArticleClik here to view.
ジャイロス・プロテイン・テクノロジーズ、日本に専用オフィスを設立
スウェーデン・ウプサラ （ビジネスワイヤ） — ナノリットルスケール・イムノアッセイ装置自動化の先駆者であり、ペプチドシンセサイザーおよびペプチド試薬のリーディングプロバイダーであるジャイロス・プロテイン・テクノロジーズは本日、日本の東京に専用オフィスを開設し、ジャイロス・ジャパン株式会社を設立したと発表しました。...
View ArticleClik here to view.
First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the first patient was dosed in the Phase I/II trial...
View ArticleClik here to view.
Clik here to view.
武田薬品とアフィロジックが研究提携契約を締結し、Nanofitin®を使用して中枢神経系疾患の治療薬開発に当たる
大阪 & 仏ナント — （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
New Standards for Forensic Grade Manufacturing Integrated At Promega
MADISON, Wis. With recent approval in meeting the new ISO 18385 standard, Promega Corporation will be including a “Forensic Grade” classification on products used for human identity by crime labs,...
View ArticleClik here to view.
Gilead Sciences and the World Health Organization Announce Five-Year Visceral...
FOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq:GILD) today announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug...
View Article